leisure time -WSS

leisure time

author：entertainment 2025-09-02 22:25:11 - browse：8

Blue CAR-T cell attacks a leukemia cell. --health coverage from STAT — Engineered receptors on the surface of a T-lymphocyte bind to a leukemia cell. Adobe

The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy had itself caused blood cancers initially appeared to be a significant blow to one of the brightest spots in cancer care.

But experts quickly cautioned that risk of this complication is probably minuscule compared to the known risk of secondary cancers from other cancer therapies like chemotherapy and radiation. They noted that CAR-T cells are immune cells that are genetically engineered to fight cancer, and that such genetic modifications were long thought to carry a risk of causing a second, new cancer in patients. The surprise, in a way, is that since CAR-T was first invented more than 10 years ago, that risk had remained just theoretical.

“There’s been a requirement for long-term follow up. I think this is why we’re all surprised. As far as I think any one of us knew, it’d never happened with any of the FDA-approved CAR-Ts,” said Marcela Maus, a cell therapy researcher at Mass General Cancer Center.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： STAT Summit: Michael J. Fox on progress in Parkinson's research

entertainment

WSS

Cue Health, Covid

STAT Summit: GSK CEO on pharma giant's new direction

Eyeing GLP

FDA gives detailed accounting of AI

Pharmacists can make shortage drugs, but at what cost?

Will Ozempic

explore

leisure time

leisure time

Hollywood unions extend contract negotiations for actors

Solve the antibiotic resistance crisis with preventive drugs

Medicare proposal to cover medical devices draws a mixed reaction

Liver decline slowed by off

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Listen: A conversation with researcher Kevin Esvelt on biosecurity

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Eyeing GLP

Drug repurposing or repositioning? The language matters

FDA gives detailed accounting of AI

focus

Lawmakers consider Medicare pay reforms for doctors

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Biogen joins immunology wave with $1.15 billion acquisition of HI

Study finds gene variants tied to breast cancer risk in Black women

FDA poised to publish guidelines for clinical trial diversity

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

entertainment

entertainment

explore

focus